| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
61,556,000 |
| Market
Cap: |
2.90(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$30.29 - $57 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drugs - Generic |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. Co.'s products include Trokendi XR and Oxtellar XR, which are the once-daily extended release topiramate and oxcarbazepine products indicated for the treatment of epilepsy; APOKYN, which is a product indicated for the intermittent treatment of hypomobility or off episodes in patients with Parkinson's Disease (PD); XADAGO, which is an once-daily product indicated as adjunctive treatment to levodopa/carbidopa in patients with PD; and MYOBLOC, which is a product indicated for the treatment of cervical dystonia and sialorrhea in adults.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
191,900 |
480,706 |
494,383 |
945,691 |
| Total Sell Value |
$9,400,868 |
$22,004,539 |
$22,546,744 |
$38,631,555 |
| Total People Sold |
2 |
6 |
8 |
10 |
| Total Sell Transactions |
8 |
23 |
27 |
43 |
| End Date |
2025-09-14 |
2025-06-13 |
2024-12-13 |
2023-12-14 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Newhall Charles W III |
Director |
– • – |
2025-11-21 |
4 |
OE |
$12.98 |
$194,700 |
D/D |
15,000 |
119,644 |
|
- |
|
| Newhall Charles W III |
Director |
– • – |
2025-10-09 |
4 |
AS |
$50.73 |
$1,269,234 |
D/D |
(25,000) |
104,644 |
|
-5% |
|
| Khattar Jack A. |
President, CEO |
• • – |
2025-10-09 |
4 |
AS |
$50.55 |
$3,029,336 |
D/D |
(59,900) |
1,206,578 |
|
-5% |
|
| Khattar Jack A. |
President, CEO |
• • – |
2025-10-09 |
4 |
OE |
$25.30 |
$2,055,625 |
D/D |
81,250 |
1,266,478 |
|
- |
|
| Khattar Jack A. |
President, CEO |
• • – |
2025-10-02 |
4 |
AS |
$48.06 |
$91,506 |
D/D |
(1,904) |
1,161,233 |
|
-2% |
|
| Khattar Jack A. |
President, CEO |
• • – |
2025-10-02 |
4 |
OE |
$25.30 |
$57,355 |
D/D |
2,267 |
1,163,137 |
|
- |
|
| Khattar Jack A. |
President, CEO |
• • – |
2025-10-02 |
4 |
D |
$46.21 |
$708,168 |
D/D |
(15,325) |
1,185,228 |
|
- |
|
| Khattar Jack A. |
President, CEO |
• • – |
2025-10-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
39,320 |
1,192,757 |
|
- |
|
| Khattar Jack A. |
President, CEO |
• • – |
2025-10-01 |
4 |
AS |
$48.07 |
$1,931,116 |
D/D |
(40,173) |
1,160,870 |
|
-2% |
|
| Khattar Jack A. |
President, CEO |
• • – |
2025-10-01 |
4 |
OE |
$25.30 |
$1,360,761 |
D/D |
53,785 |
1,201,043 |
|
- |
|
| Khattar Jack A. |
President, CEO |
• • – |
2025-09-30 |
4 |
AS |
$48.25 |
$414,371 |
D/D |
(8,588) |
1,147,258 |
|
-1% |
|
| Khattar Jack A. |
President, CEO |
• • – |
2025-09-30 |
4 |
OE |
$25.30 |
$291,203 |
D/D |
11,510 |
1,155,846 |
|
- |
|
| Khattar Jack A. |
President, CEO |
• • – |
2025-09-29 |
4 |
AS |
$48.02 |
$491,485 |
D/D |
(10,235) |
1,144,336 |
|
-1% |
|
| Khattar Jack A. |
President, CEO |
• • – |
2025-09-29 |
4 |
OE |
$25.30 |
$346,306 |
D/D |
13,688 |
1,154,571 |
|
- |
|
| Rubin Jonathan |
SVP, Chief Medical Officer |
• – – |
2025-09-25 |
4 |
D |
$46.21 |
$38,816 |
D/D |
(840) |
11,015 |
|
- |
|
| Rubin Jonathan |
SVP, Chief Medical Officer |
• – – |
2025-09-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,875 |
11,855 |
|
- |
|
| Khattar Jack A. |
President, CEO |
• • – |
2025-09-23 |
4 |
AS |
$47.23 |
$1,393,899 |
D/D |
(29,513) |
1,140,883 |
|
1% |
|
| Khattar Jack A. |
President, CEO |
• • – |
2025-09-23 |
4 |
OE |
$12.98 |
$622,261 |
D/D |
47,940 |
1,170,396 |
|
- |
|
| Khattar Jack A. |
President, CEO |
• • – |
2025-09-22 |
4 |
AS |
$47.02 |
$779,921 |
D/D |
(16,587) |
1,122,456 |
|
0% |
|
| Khattar Jack A. |
President, CEO |
• • – |
2025-09-22 |
4 |
OE |
$12.98 |
$351,239 |
D/D |
27,060 |
1,139,043 |
|
- |
|
| Mottola Frank |
SVP, Chief Tech. Ops. Officer |
• – – |
2025-09-12 |
4 |
S |
$45.87 |
$229,350 |
D/D |
(5,000) |
15,496 |
|
-2% |
|
| Mottola Frank |
SVP, Chief Tech. Ops. Officer |
• – – |
2025-09-12 |
4 |
OE |
$39.40 |
$197,000 |
D/D |
5,000 |
20,496 |
|
- |
|
| Khattar Jack A. |
President, CEO |
• • – |
2025-09-08 |
4 |
AS |
$46.29 |
$292,645 |
D/D |
(6,322) |
1,111,983 |
|
3% |
|
| Khattar Jack A. |
President, CEO |
• • – |
2025-09-08 |
4 |
OE |
$25.30 |
$204,272 |
D/D |
8,074 |
1,118,305 |
|
- |
|
| Khattar Jack A. |
President, CEO |
• • – |
2025-09-05 |
4 |
AS |
$46.01 |
$2,557,144 |
D/D |
(55,578) |
1,110,231 |
|
3% |
|
384 Records found
|
|
Page 1 of 16 |
|
|
0.65 (1.4%) 
